The global cancer antibody drug conjugates market is experiencing significant expansion, with a projected increase from $8.19 billion in 2024 to $9.17 billion in 2025, reflecting ...
You may have heard of the consulting firm Gartner’s technology hype cycle—the technology trigger, the peak of inflated expectations, the trough of disillusionment, the slope of enlightenment, and the ...
Biotium, a leading developer of fluorescent reagents for life science research, is proud to introduce ActinBrite™ High Affinity Phalloidin Conjugates — a new generation of fluorescent phalloidin ...
From hair regrowth to safe pregnancy chemotherapy and new targeted therapies, these top five breast cancer stories of 2025 ...
Probody drug conjugates, immune-stimulating antibody conjugates, engineered toxin bodies, radioligand conjugates, and so on comprise the new wave of molecules in clinical development, seeking to ...
The hottest cancer technology from the turn of the century is finally getting its glow-up moment, as clinical trials continue to show that antibody-drug conjugates (ADCs) perform better than standard ...
Antibody-drug conjugates select ADCs) were initially developed to provide a selective targeting mechanism for cytotoxic small molecule drugs with the goal of improving the therapeutic index in ...
Researchers identified predictors of immunotherapy response in advanced bladder cancer, including tumor mutational burden and APOBEC mutational signature. The FDA-approved combination of Keytruda and ...
Lonza has extended its antibody-drug conjugate (ADC) manufacturing contract with a major biopharmaceutical customer, according to a press statement, which does not name the client. Lonza says that as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback